DrugPatentWatch Database Preview

RITUXAN Drug Profile

« Back to Dashboard

Summary for Tradename: RITUXAN

Patents:	678
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RITUXAN

Pharmacology for RITUXAN

Mechanism of Action

CD20-directed Antibody Interactions

US Patents for RITUXAN

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		Bayer Intellectual Property GMBH (Monheim, DE)		RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		Alexion Pharmaceuticals, Inc. (New Haven, CT)		RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		Astellas Pharma Inc. (Tokyo, JP)		RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		LegoChem Biosciences, Inc. (Daejeon, KR)		RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		Genentech, Inc. (South San Francisco, CA) Biogen Idec Inc. (Cambridge, MA)		RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26				RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26		Beth Israel Deaconess Medical Center, Inc. (Boston, MA) Emory University (Atlanta, GA)		RX		search

International Patents for RITUXAN

Country	Patent Number	Estimated Expiration
South Korea	20100125240
European Patent Office	2177620
Russian Federation	2010148743
Eurasian Patent Organization	201170040
Taiwan	201231089
Israel	212390
Argentina	079234

Supplementary Protection Certificates for RITUXAN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122017000101	Germany		PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
PA2017036	Lithuania		PRODUCT NAME: INOTUZUMABO OZOGAMICINAS; REGISTRATION NO/DATE: EU/1/17/1200 20170629
PA2017038	Lithuania		PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
2018C/020	Belgium		PRODUCT NAME: EEN GEAFUCOSYLEERD ANTILICHAAM DAT BINDT AAN DE ALFA-SUBEENHEID VAN DE INTERLEUKINE-5- RECEPTOR, IN HET BIJZONDER BENRALIZUMAB OF EEN THERAPEUTISCH EQUIVALENTE VARIANT DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/17/1252 20180110
C20150014 00145	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
122016000049	Germany		PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
CA 2015 00006	Denmark		PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805